Hepatitis Monthly

Published by: Kowsar

The Liver MicroRNA Expression Profiles Associated With Chronic Hepatitis C Virus (HCV) Genotype-4 Infection: A Preliminary Study

Nadia Mohamed El-Guendy 1 , Reham Helwa 2 , Medhat Salah El-Halawany 3 , Shimaa Abdel Rahman Ali 1 , Marwa Tantawy Aly 4 , Nelly Hasan Alieldin 5 , Shawky Abdel Hamid Fouad 6 , Hany Saeid 7 and Abdel-Hady Ali Abdel-Wahab 1 , *
Authors Information
1 Department of Cancer Biology, National Cancer Institute, Cairo University, Cairo, Egypt
2 Department of Zoology, Faculty of Science, Ain Shams University, Cairo, Egypt
3 Department of Zoology, Faculty of Science, Cairo University, Cairo, Egypt
4 Research Department, Children’s Cancer Hospital, Cairo, Egypt
5 Department of Biostatistics and Cancer Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt
6 Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
7 Department of General Surgery, Ain Shams University, Cairo, Egypt
Article information
  • Hepatitis Monthly: April 01, 2016, 16 (4); e33881
  • Published Online: March 20, 2016
  • Article Type: Research Article
  • Received: October 26, 2015
  • Revised: February 12, 2016
  • Accepted: February 23, 2016
  • DOI: 10.5812/hepatmon.33881

To Cite: El-Guendy N M, Helwa R, El-Halawany M S, Abdel Rahman Ali S, Tantawy Aly M, et al. The Liver MicroRNA Expression Profiles Associated With Chronic Hepatitis C Virus (HCV) Genotype-4 Infection: A Preliminary Study, Hepat Mon. 2016 ; 16(4):e33881. doi: 10.5812/hepatmon.33881.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Hepatitis C. 2014;
  • 2. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther. 2005; 10(1): 1-11[PubMed]
  • 3. Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010; 30(9): 1259-69[DOI][PubMed]
  • 4. Sharma NK, Sherker AH. Chronic viral hepatitis Diagnosis and Therapeutics. 2009; : 33-70
  • 5. Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology. 2008; 47(4): 1371-83[DOI][PubMed]
  • 6. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012; 13(4): 271-82[DOI][PubMed]
  • 7. Gupta A, Swaminathan G, Martin-Garcia J, Navas-Martin S. MicroRNAs, hepatitis C virus, and HCV/HIV-1 co-infection: new insights in pathogenesis and therapy. Viruses. 2012; 4(11): 2485-513[DOI][PubMed]
  • 8. Shimakami T, Yamane D, Welsch C, Hensley L, Jangra RK, Lemon SM. Base pairing between hepatitis C virus RNA and microRNA 122 3' of its seed sequence is essential for genome stabilization and production of infectious virus. J Virol. 2012; 86(13): 7372-83[DOI][PubMed]
  • 9. Yoshikawa T, Takata A, Otsuka M, Kishikawa T, Kojima K, Yoshida H, et al. Silencing of microRNA-122 enhances interferon-alpha signaling in the liver through regulating SOCS3 promoter methylation. Sci Rep. 2012; 2: 637[DOI][PubMed]
  • 10. Pan QW, Henry SD, Scholte BJ, Tilanus HW, Janssen HL, van der Laan LJ. New therapeutic opportunities for hepatitis C based on small RNA. World J Gastroenterol. 2007; 13(33): 4431-6[PubMed]
  • 11. Kwon YC, Ray RB, Ray R. Hepatitis C virus infection: establishment of chronicity and liver disease progression. Excli j. 2014; 13: 977-96[PubMed]
  • 12. Bandyopadhyay S, Friedman RC, Marquez RT, Keck K, Kong B, Icardi MS, et al. Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. J Infect Dis. 2011; 203(12): 1753-62[DOI][PubMed]
  • 13. Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray RB. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J Virol. 2012; 86(18): 10221-5[DOI][PubMed]
  • 14. Katze MG, Fornek JL, Palermo RE, Walters KA, Korth MJ. Innate immune modulation by RNA viruses: emerging insights from functional genomics. Nat Rev Immunol. 2008; 8(8): 644-54[DOI][PubMed]
  • 15. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 2007; 449(7164): 919-22[DOI][PubMed]
  • 16. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013; 10(9): 542-52[DOI][PubMed]
  • 17. Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol. 2013; 5(9): 479-86[DOI][PubMed]
  • 18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2): 289-93[DOI][PubMed]
  • 19. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10(6)[DOI][PubMed]
  • 20. Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol. 2008; 82(16): 8215-23[DOI][PubMed]
  • 21. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005; 309(5740): 1577-81[DOI][PubMed]
  • 22. Spaniel C, Honda M, Selitsky SR, Yamane D, Shimakami T, Kaneko S, et al. microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. PLoS One. 2013; 8(10)[DOI][PubMed]
  • 23. Martin M, Herceg Z. From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms. Genome Med. 2012; 4(1): 8[DOI][PubMed]
  • 24. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology. 2009; 49(4): 1098-112[DOI][PubMed]
  • 25. Choi Y, Dienes HP, Krawczynski K. Kinetics of miR-122 expression in the liver during acute HCV infection. PLoS One. 2013; 8(10)[DOI][PubMed]
  • 26. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol. 2013; 58(2): 234-9[DOI][PubMed]
  • 27. Estrabaud E, Lapalus M, Broet P, Appourchaux K, De Muynck S, Lada O, et al. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol. 2014; 88(11): 6394-402[DOI][PubMed]
  • 28. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med. 2009; 15(1): 31-3[DOI][PubMed]
  • 29. Roy S, Benz F, Luedde T, Roderburg C. The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis. Hepatobiliary Surg Nutr. 2015; 4(1): 24-33[DOI][PubMed]
  • 30. Haneklaus M, Gerlic M, O'Neill LA, Masters SL. miR-223: infection, inflammation and cancer. J Intern Med. 2013; 274(3): 215-26[DOI][PubMed]
  • 31. Li S, Duan X, Li Y, Liu B, McGilvray I, Chen L. MicroRNA-130a inhibits HCV replication by restoring the innate immune response. J Viral Hepat. 2014; 21(2): 121-8[DOI][PubMed]
  • 32. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011; 53(1): 209-18[DOI][PubMed]
  • 33. Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, Matsuda F, et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One. 2011; 6(1)[DOI][PubMed]
  • 34. Sun B, Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene. 2008; 27(48): 6228-44[DOI][PubMed]
  • 35. Gao Z, Dou Y, Chen Y, Zheng Y. MicroRNA roles in the NF- kappaB signaling pathway during viral infections. 2014; 2014: 436097[DOI][PubMed]
  • 36. Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, et al. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene. 2008; 27(34): 4712-23[DOI][PubMed]
  • 37. Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu ZG. MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. Nat Immunol. 2010; 11(9): 799-805[DOI][PubMed]
  • 38. Jia L, Wu J, Zhang L, Chen J, Zhong D, Xu S, et al. Restoration of miR-1228* expression suppresses epithelial-mesenchymal transition in gastric cancer. PLoS One. 2013; 8(3)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments